Dr Powels talks to ecancer at ESMO 2023 in Madrid about his presentation on
the phase 3 EV-302 clinical trial, also known as KEYNOTE-A39, evaluating the combination of enfortumab vedotin-ejfv and pembrolizumab) compared to chemotherapy, for patients with previously untreated locally advanced or metastatic urothelial cancer.
The study showed improvements in overall survival (OS) and progression-free survival (PFS).
Patients receiving enfortumab vedotin and pembrolizumab had a median OS of 31.5 months compared to 16.1 months with chemotherapy. OS risk reduced by 53% with the combination therapy. Median PFS was 12.5 months compared to 6.3 months in the chemotherapy arm, reducing the risk of cancer progression or death by 55%, and the study showed consistent OS results across various patient subgroups.
Common Grade 3 or higher adverse events related to the combination therapy included rash, hyperglycaemia, neutropenia, neuropathy, diarrhoea, and anaemia, with no new safety concerns identified.
